[NICE Technology appraisal guidance] Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

NICE | February 2019 | Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.

Full details from NICE 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s